Idursulfase (Elaprase)
Enzyme replacement therapy (recombinant iduronate-2-sulfatase)
Idursulfase (Elaprase)
Forms and strengths
Form: TabletStrength: 2 mg/mL (6 mg/3 mL vial)
References
Indication
- Idursulfase is used for long-term enzyme replacement therapy in patients with Hunter syndrome (mucopolysaccharidosis II, MPS II).
Pregnancy
- There are no data on idursulfase use in pregnant women; animal studies show that idursulfase crosses into fetal circulation.
- Idursulfase should not be given during pregnancy except when the clinical need is clear and the potential benefit is judged to substantially outweigh the risk.
Breastfeeding
- Animal studies show idursulfase is excreted in breast milk, so caution should be used when giving idursulfase to a nursing woman after weighing the risks and benefits.
Geriatrics
- Studies in patients over 65 years of age have not been performed, so safety and efficacy in this population are not established.
Pediatrics
- Clinical studies included patients as young as 16 months of age, and children, adolescents, and adults responded similarly to treatment.
- Pediatric patients with the complete-deletion, large-rearrangement genotype have a higher probability of developing antibodies, including neutralizing antibodies, and infusion-related events, along with a more muted treatment response.
Dosage & Administration
- The recommended dose is 0.5 mg/kg body weight given once weekly by intravenous infusion.
- The infusion is given over 3 hours initially, which may be gradually reduced to 1 hour if well tolerated; infusion time should never exceed 8 hours.
- The initial infusion rate is 8 mL/hr for the first 15 minutes, increased by 8 mL/hr every 15 minutes if tolerated, but never exceeding 100 mL/hr.
- The infusion rate may be slowed or temporarily stopped if an infusion-related reaction occurs.
- The calculated dose must be diluted in 100 mL of 0.9% sodium chloride injection using strict aseptic technique, and administered through a 0.2 micrometer in-line filter without mixing with other products.
- Diluted solution should be used within 8 hours at room temperature or within 24 hours if refrigerated.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Overdose experience is limited to a single reported case.
- In that case, a patient who received idursulfase at twice the recommended dose for about 1.5 years developed two anaphylactic reactions occurring several years after starting treatment.
Common side effects
- Headache is very common.
- Fever (pyrexia) is very common.
- Rash is very common.
- Itching (pruritus) is very common.
- Hives (urticaria) is very common.
- Chest pain is very common.
- Hypertension is very common.
- Infusion site swelling is common.
- Nausea is common.
- Dyspepsia (indigestion) is common.
- Abdominal pain is common.
- Diarrhea is common.
- Cough is common.
- Wheezing is common.
- Flushing is common.
- Dizziness is common.
- Upper respiratory tract infection is common in children.
- Muscle or bone pain may occur.
- Nasal congestion and sore throat may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Anaphylactoid or anaphylactic reactions, which can be life-threatening, have occurred up to several years after starting treatment, and late-emergent symptoms can appear as long as 24 hours after an initial reaction.
- Hypoxic episodes requiring oxygen therapy have occurred during infusions, particularly in patients with underlying obstructive airway disease.
- A seizure occurred in one patient during an infusion given while the patient had a febrile respiratory illness.
- Serious exacerbation of respiratory or cardiac status can occur during infusion in patients susceptible to fluid overload or with compromised cardiac or respiratory function.
- Angioedema has been reported as part of allergic reactions to idursulfase.
- Cardiac arrhythmia and rapid or irregular heartbeat have been reported during or after infusion.
- Pulmonary embolism has been reported in a patient with pre-existing cardiac disease.
- Fatal outcomes have been reported, including cardiac failure, cardiorespiratory arrest, pneumonia, respiratory distress, and respiratory failure.
- About half of treated patients develop anti-idursulfase antibodies, which can reduce the drug's effect on clearing glycosaminoglycans (GAG).
- Seek urgent medical attention for difficulty breathing, wheezing, swelling of the face or throat, chest pain, seizures, or a rapid drop in blood pressure during or after an infusion.
Use with caution
- Use with caution in patients susceptible to fluid overload, or those with compromised cardiac or respiratory function requiring fluid restriction.
- Use with caution in patients with severe underlying airway disease, who should be closely monitored in an appropriate clinical setting with supplemental oxygen readily available.
- Use with caution and consider delaying infusion in patients with an acute febrile respiratory illness.
- Use with caution regarding antihistamine and other sedative medications in patients with respiratory compromise, since these can complicate management of infusion reactions.
- Use with caution in patients who previously developed hypersensitivity reactions; re-treatment is at the discretion of the healthcare provider after successful management of symptoms.
- No studies have been conducted in patients with hepatic or renal impairment, so caution is warranted in these populations.
Contraindications
- Contraindicated in patients with known hypersensitivity to idursulfase or to any ingredient in the formulation or container.
Drug interactions
- No formal drug interaction studies have been conducted with idursulfase.
- Based on its breakdown by cellular lysosomal proteolysis, idursulfase is not expected to be involved in cytochrome P450-mediated drug interactions.
Food interactions
- No food interactions have been established for this intravenous enzyme replacement therapy.
Time of administration
- Idursulfase is administered once weekly by intravenous infusion under medical supervision, not tied to meals or a specific time of day.
Storage
- Store at 2°C to 8°C (refrigerated), protected from light; do not freeze or shake.
- Do not use after the expiration date on the vial.
Patient take-away
- Elaprase is a weekly intravenous enzyme replacement infusion for Hunter syndrome (MPS II), given under medical supervision, typically over 1 to 3 hours.
- Infusion-related reactions such as rash, itching, fever, and flushing are common, especially early in treatment, and tend to decrease with continued use.
- Serious allergic reactions can occur, sometimes years into treatment and even hours after the infusion ends, so seek urgent care for breathing difficulty, facial swelling, or severe chest pain.
- Tell your healthcare professional about any breathing problems, heart conditions, or previous reactions to Elaprase before each infusion.